DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hypertrichosis — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypertrichosis maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypertrichosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
N-acetyl-alpha-glucosaminidase (NAGLU) — NAGLU is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet xyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4XWH · 2.32 Å · ligand Xylitol (XYL). Experimental structure, not a prediction.
What the evidence adds up to
Inherited hypertrichoses are rare and genetically heterogeneous, with more than 50 OMIM entries and at least nine distinct clinical entities identified by 2002, though few had a localised gene locus or candidate gene. A 1997 linkage-mapping study for X-linked dominant congenital generalised hypertrichosis defined an extremely large candidate region, and a 2002 review noted that the results were not clinically useful and that identification of the gene was not imminent. No drug treatment is mentioned in any of these abstracts.
A 1985 case report describes a 3-month-old female infant with congenital hypertrichosis of the trunk and proximal extremities; biopsy showed normal hair follicles and discrete bundles of spindle cells in the dermis. A 2017 case report describes a 5-year-old girl with multiple patches of localised hypertrichosis at unusual sites without any systemic abnormality. A 2020 paper defines hypertrichosis as hair growth abnormal for age, sex, race, or body part, distinguishes it from hirsutism, and classifies it by onset, distribution, and hair type, but does not report any treatment or intervention.
The abstracts provide no data on survival, response rates, or sample sizes for any drug in hypertrichosis. No drug is named or tested. What is missing is any clinical trial, any drug repurposing study, any patient stratification by genetic subtype, and any funding for such work.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 2002 · 38 citations
Inherited hypertrichoses
AbstractHypertrichosis is a rare condition characterized by excessive growth of hair (terminal, vellus or lanugo) in areas of the body that are not predominantly androgen dependent, and it is independent of age, race or sex. It can be congenital, late-onset, generalized, localized, inherited or acquired. More than 50 different OMIM entries related to hypertrichosis exist, few of them with a localized gene locus or with a candidate gene. The review of generalized hypertrichoses from a historical point of view, including a review of their clinical and genetic features, shows heterogeneity with at least nine different entities. A short analysis of other forms of hypertrichosis is presented.
Abstract<h3>REPORT OF A CASE</h3> A 3-month-old female infant was seen at Children's Memorial Hospital, Chicago, for evaluation of hypertrichosis of the trunk and proximal extremities that had been present since birth. She was the product of an uncomplicated full-term pregnancy and vaginal delivery. Her growth and development were normal. The patient's mother reportedly had a history of hypertrichosis, but additional details of the family history were unavailable. Physical examination revealed excessive hair on the presacral area, buttocks, thighs, shoulders, and upper arms (Figs 1 and 2). On palpation, there was minimal induration in some of the hypertrichotic areas but no apparent tenderness. There was no associated alteration in pigmentation. Two biopsy specimens were obtained, one from the left posterior shoulder and the other from the right buttock. Sections from both areas showed several normal-appearing hair follicles along with numerous discrete bundles of spindle cells scattered throughout the dermis (Fig 3).
Indian Journal of Paediatric Dermatology · 2017 · 1 citations · open access
Localized hypertrichosis at unusual sites
AbstractLocalized hypertrichosis is a rare entity characterized by circumscribed patches of terminal hair. It may be associated with many underlying systemic abnormalities. In our case, a 5-year-old girl presented with complaints of multiple patches of hypertrichosis without any systemic abnormality since the last 4 years. We are reporting this case due to the rarity of hypertrichosis at abnormal sites.
Journal of Cutaneous Medicine and Surgery · 1997 · 0 citations
Genetic Studies in Skin Disorders, No. 1: Hair Today—Hair Tomorrow
AbstractBackground: A high-profile genetics journal published an article describing the mapping of a gene for the X-linked dominant disorder congenital generalized hypertrichosis. Objective: This article evaluates the data presented by Figuera et al. in their linkage-mapping study. Methods: The size of the candidate region defined by Figuera et al., the power of the data to identify candidate loci within the region, and the usefulness of the results for clinicians are evaluated. Results: The candidate region identified by Figuera et al. is extremely large, and these results will not be clinically useful. Conclusion: Despite what may have been presented in the lay press, identification of the gene for congenital generalized hypertrichosis is not imminent.
Archives of Disease in Childhood · 2020 · 0 citations
Mind the gap: understanding medication side effects
AbstractHypertrichosis is hair growth abnormal for age, sex or race or for a particular body part. It must be distinguished from hirsutism, which is male pattern hair growth in a female or child.1 2 Hypertrichosis is classified based on age of onset (congenital vs acquired), distribution (localised vs generalised) and type of hair (vellus vs terminal).3
A growth-restricted female infant required a high glucose …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
